WS
INO icon

Wedbush Securities’s Inovio Pharmaceuticals INO Stock Holding History

Wedbush Securities’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,375
Closed -$34K – 1011
2019
Q3 		$34K Buy
+1,375
New +$41.8K ﹤0.01% 959

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wedbush Securities's INO Position: Q4 2019 in Review

Wedbush Securities sold out of Inovio Pharmaceuticals (INO) in Q4 2019, closing a stake of 1,375 shares — an estimated $34K sold.

Wedbush Securities first reported a position in INO in Q3 2019 and held it in 1 quarter. The position peaked at $34K in Q3 2019. 106 funds tracked by Wall St. Rank hold INO as of Q4 2019.

  • Wedbush Securities reported no remaining Inovio Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Wedbush Securities sold 1,375 Inovio Pharmaceuticals shares in Q4 2019, an estimated $34K.
  • Wedbush Securities first reported a position in Inovio Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Wedbush Securities's Inovio Pharmaceuticals position peaked at $34K in Q3 2019.
  • 106 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2019.

Based on Wedbush Securities's 13F filing for Q4 2019, filed 16 Jan 2020.